<?xml version="1.0" encoding="UTF-8"?>
<p id="p0215">In February 2017, the European Union (EU) approved Baricitinib 
 <bold>(10)</bold> as second-line oral treatment for mild to severe active rheumatoid arthritis in adults (
 <xref rid="f0015" ref-type="fig">Fig. 3</xref>).
 <xref rid="b0045" ref-type="bibr">
  <sup>9</sup>
 </xref> A differential feature of Baricitinib structure is the azetidine ring bearing an ethylsulfonyl, beyond an acetonitrile group at 3-position. The same ring binds to the N atom at 1-position in the pyrazole, which, in its turn, binds to the pyrimidine conjugated to a pyrrole ring.
 <xref rid="b0500" ref-type="bibr">
  <sup>100</sup>
 </xref> This medicine can modulate human innate and adaptive immune system. Based on this property, presumably, one of the important mechanisms of action of baricitinib in the treatment of rheumatoid arthritis is the inhibition of the IL-6 / JAK1 / JAK2 pathway.
 <xref rid="b0505" ref-type="bibr">
  <sup>101</sup>
 </xref>
</p>
